Sahajanand Medical Technologies IPO
Closed TodayIPOListing at: BSE, NSE • Sahajanand Estate, Wakharia Wadi,NR. Dabholi Char RastaNani Ved, Ved RoadSurat, Gujarat, 395004
Disclaimer: GMP values change dynamically. This data is strictly for educational purposes only and not an investment advice.
Sahajanand Medical Technologies IPO GMP History
Genuine daily snapshots retained by the WeeStox backendDisclaimer: GMP values change dynamically. This data is strictly for educational purposes only and not an investment advice.
| GMP date | IPO price | GMP | Premium | Est. profit / lot | Subscription | Movement |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | ₹344 | +₹25 | 7.27% | +₹1,075 | 0.83x | ↓ Down |
| 18 Oct 2026 | ₹344 | +₹28 | 8.14% | +₹1,204 | 0.83x | ↑ Up |
| 17 Oct 2026 | ₹344 | +₹15 | 4.36% | +₹645 | 0.83x | ↓ Down |
| 16 Oct 2026 | ₹344 | +₹35 | 10.17% | +₹1,505 | 0.83x | ↓ Down |
| 15 Oct 2026 | ₹344 | +₹43 | 12.50% | +₹1,849 | 0.35x | ↑ Up |
| 14 Oct 2026 | ₹344 | +₹41 | 11.92% | +₹1,763 | - | Flat |
| 13 Oct 2026 | ₹344 | +₹41 | 11.92% | +₹1,763 | - | Flat |
Explore the complete GMP movement
Open the chart and all available daily records.
Sahajanand Medical Technologies IPO Details
| IPO Date | 15 Oct 2026 to 19 Oct 2026 |
| Listing At | BSE, NSE |
| Face Value | ₹1 per share |
| Price Band | ₹344 |
| Lot Size | 43 Shares |
| Total Issue Size | ₹475.48 Cr(₹1,255.57 Cr) |
| Fresh Issue | – |
| Offer for Sale (OFS) | ₹475 Cr (approx 2.74 Cr shares) |
| Issue Type | Book Built Issue IPO |
Sahajanand Medical Technologies IPO Timetable
| IPO Open Date | 15 Oct 2026 |
| IPO Close Date | 19 Oct 2026 |
| Basis of Allotment | 21 Oct 2026 |
| Initiation of Refunds | 22 Oct 2026 |
| Credit of Shares to Demat | 22 Oct 2026 |
| Listing Date | 23 Oct 2026 |
| Cut-off time for UPI Mandate | 5 PM on 19 Oct 2026 |
| Employee Discount | ₹20.00/share (Up to 52,083 shares) |
Sahajanand Medical Technologies IPO Reservation
| Category | Reservation | Shares Offered |
|---|---|---|
| Anchor Shares Offered | 29.46% | 40,71,634 |
| QIB Shares Offered | 19.64% | 27,14,424 |
| HNI Shares Offered | 14.73% | 20,35,817 |
| Retail Shares Offered | 34.37% | 47,50,241 |
| Employee Shares Offered | 1.81% | 2,50,000 |
| Total Shares Offered | 100.00% | 1,38,22,116 |
Sahajanand Medical Technologies Anchor Details
| Anchor Bid Date | 14 Oct 2026 |
| Anchor Shares Offered | 40,71,634 Shares |
| Total Anchor Portion | ₹140.06 Cr |
| Lock-in 50% End Date | 20 Nov 2026 (30 Days) |
| Lock-in Rem. 50% Date | 19 Jan 2027 (90 Days) |
Sahajanand Medical Technologies IPO Lot Size
| Application | Lots | Shares | Amount (Cut-off) | Reserved Applications |
|---|---|---|---|---|
| Retail (Min) | 1 Lot | Shares | ₹14,792 | – |
| Retail (Max) | 13 Lots | Shares | ₹1,92,296 | – |
| S-HNI (Min) | 14 Lots | Shares | ₹2,07,088 | – |
| S-HNI (Max) | 67 Lots | Shares | ₹9,91,064 | – |
| B-HNI (Min) | 68 Lots | Shares | ₹10,05,856 | – |
Sahajanand Medical Technologies Promoter Holding
| Pre-Issue Holding | Disclosed in RHP |
| Post-Issue Holding | To be calculated |
Sahajanand Medical Technologies IPO Broker Consensus & Reviews
Institutional and brokerage house recommendations with verified review reports| Broker / Research Firm | Recommendation | Research Report |
|---|---|---|
| Capital Market | Neutral | View Review |
| SMC Global | Neutral | View Review |
| Ventura Securities Limited | Apply | View Review |
| GEPL Capital Ltd | Apply | View Review |
| BP Equities (BP Wealth) | Apply | View Review |
Sahajanand Medical Technologies IPO Live Subscription Status
Bidding demand breakdown by shares, institutional demand in ₹ Cr, applications & HNI funding cost| Investor Category | Shares Offered | Shares Bidded | Subscription Times |
|---|---|---|---|
| QIBs | 27,14,424 | 30,48,700 | 1.12x |
| HNIs | 20,35,817 | 10,42,836 | 0.51x |
| ↳ HNIs 10+ | 13,57,212 | 5,17,118 | 0.38x |
| ↳ HNIs 2+ | 6,78,606 | 5,25,718 | 0.77x |
| Retail | 47,50,241 | 40,32,282 | 0.85x |
| Employees | 2,50,000 | 35,002 | 0.14x |
| Total | 97,50,482 | 81,58,820 | 0.84x |
| QIBs | 93 | 105 | 1.12x |
| FIIs | – | 20 | 0.00x |
| DIIs | – | – | 0.00x |
| Mutual funds | – | 10 | 0.00x |
| Others | – | 75 | 0.00x |
| HNIs | 70 | 36 | 0.51x |
| ↳ HNIs 10+ | 47 | 18 | 0.38x |
| ↳ HNIs 2+ | 23 | 18 | 0.77x |
| Retail | 163 | 139 | 0.85x |
| Employees | 9 | 1 | 0.14x |
| Total | 335 | 281 | 0.84x |
Sahajanand Medical Technologies Limited Financial Information (Restated Consolidated in ₹ Crores)
| Period Ended | Assets | Total Income | Profit After Tax | EBITDA | Net Worth | Total Borrowing |
|---|---|---|---|---|---|---|
| 30 Jun 2026 | ₹1309.00 Cr | ₹354.33 Cr | ₹15.09 Cr | ₹48.58 Cr | ₹631.72 Cr | ₹320.63 Cr |
| 31 Mar 2026 | ₹1276.43 Cr | ₹1218.73 Cr | ₹69.08 Cr | ₹170.66 Cr | ₹616.05 Cr | ₹269.53 Cr |
| 31 Mar 2025 | ₹1094.90 Cr | ₹1035.96 Cr | ₹25.15 Cr | ₹128.02 Cr | ₹545.23 Cr | ₹224.96 Cr |
| 31 Mar 2024 | ₹970.58 Cr | ₹908.59 Cr | ₹-7.35 Cr | ₹110.05 Cr | ₹526.30 Cr | ₹175.27 Cr |
Sahajanand Medical Technologies Key Valuation & Financial KPIs
Sahajanand Medical Technologies IPO Analysis
Review the company's key advantages and material business risks.
Strengths & Positives
Competitive advantages and operational merits
Sahajanand Medical Technologies Limited was founded in 2001 by Mr. Dhirajlal Kotadia and is a Class III and Class C/D medical devices company offering a portfolio of technologically advanced products across Vascular Intervention (VI) and Structural Heart (SH) segments. The company was the first in the world to receive CE certification for a biodegradable polymer-based drug-eluting stent (Infinnium).
Technologically Advanced Product Portfolio: The company is among a select few Class III (and Class C/D) players globally offering a comprehensive portfolio of advanced cardiovascular implants including DES, PTCA balloons, TAVI systems and Occluders, supported by strong clinical evidence and compliant with stringent domestic and international regulatory standards.
Proven R&D Capabilities: The company operates two R&D facilities in India and Thailand supported by 156 professionals, and holds over 119 patents granted globally with 78 applications pending, enabling continuous product innovation such as the proprietary LDZ link and patented AVDC system.
Leadership in India and Key International Markets: The company holds nearly 25% market share by DES sales volume in India in Fiscal 2026, and is among the top five companies by DES sales volume in Germany, Spain, Poland and Brazil, and among the top five by Occluder sales volume in Thailand, South Korea and India.
Extensive Regulatory Requirements Across Jurisdictions: The company is subject to rigorous regulation across geographies including India's Drugs and Cosmetics Act and the EU Medical Device Regulation, and any adverse regulatory action, delay in approvals, or failure to maintain certifications could adversely affect its ability to market products and its business prospects.
Dependence on Suppliers for Raw Materials: The company's top 10 suppliers contributed 63.61%, 59.15%, 64.37% and 58.88% of total purchases in the three months ended June 30, 2026 and in Fiscals 2026, 2025 and 2024 respectively, and it relies on a limited number of suppliers or a single supplier for certain critical materials, exposing it to supply and pricing volatility.
About Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies IPO is a book build issue of ₹475.48 crores. The issue is entirely an offer for sale of 1.38 crore shares of ₹475.48 crore.Sahajanand Medical Technologies IPO bidding opened for subscription on Oct 15, 2026 and will close on Oct 19, 2026. The allotment for the Sahajanand Medical Technologies IPO is expected to be finalized on Oct 21, 2026. Sahajanand Medical Technologies IPO will list on NSE and BSE with a tentative listing date fixed as Oct 23, 2026.Sahajanand Medical Technologies IPO is set issue price band at ₹327 to ₹344 per share. The lot size for an application is 43 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,792 (43 shares) (based on upper price).Motilal Oswal Investment Advisors Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.Refer to Sahajanand Medical Technologies IPO RHP for detailed Information.
Shariah Compliance Screening (AAOIFI Standard 21)
Sahajanand Medical Technologies IPO Documents & Reports
Official prospectus, reports and regulatory filings| Document Title | Authority / Host | Status | Action |
|---|---|---|---|
Red Herring Prospectus (RHP) Complete offer document filed with ROC & SEBI | SEBI / ROC | Available | View RHP |
Draft Red Herring Prospectus (DRHP) Initial regulatory draft submitted for public comments | SEBI Filings | Filed | View DRHP |
Anchor Investor Allocation Report Allotment list to institutional bidders | BSE / NSE Circular | Disclosed | Anchor PDF |
IPO Allotment Status & Basis of Allotment Registrar query portal via PAN / Application No. | MUFG Intime India Pvt.Ltd. | Live Portal | Check Allotment |
Corporate Website & Investor Relations Official portal and financial reports | Issuer Portal | Active | Visit Portal |
Sahajanand Medical Technologies IPO Registrar & Lead Managers
- Motilal Oswal Investment Advisors Ltd.
- Avendus Capital Pvt.Ltd.
- HSBC Securities & Capital Markets (India) Pvt.Ltd.
- Nuvama Wealth Management Ltd.
Sahajanand Estate, Wakharia Wadi,NR. Dabholi Char RastaNani Ved, Ved RoadSurat, Gujarat, 395004
Sahajanand Medical Technologies IPO FAQs
What is IPO GMP, and does it guarantee a listing gain?
Grey market premium is an unofficial price indication outside the exchange. It can change quickly and does not guarantee the exchange listing price, liquidity or a profit. Read it alongside the prospectus, valuation, financials and risks.
How do I check Sahajanand Medical Technologies IPO allotment status?
Open the individual IPO report and check its allotment update and registrar details. Confirm your application outcome through the official registrar or exchange service. A scheduled allotment date is not confirmation that allotment has been declared.
What does IPO subscription mean?
Subscription compares shares bid for with shares offered in a category. For example, 2 times subscription means bids for twice the available shares in that category. Retail, institutional and other categories can have different demand; subscription alone does not establish investment quality.
How is an indicative IPO listing price calculated from GMP?
A commonly used illustration adds reported GMP to the issue price, or upper price band before the final price is known. It is a sentiment illustration, not an exchange quote or reliable forecast. Missing GMP should not be interpreted as zero.
Where can I find IPO dates, price bands and lot sizes?
The individual IPO report brings together available issue dates, price bands, lot sizes, subscription and company details. Check the final prospectus and exchange announcements before applying because issue terms can change.